Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

240.50CHF
8 Dec 2017
Change (% chg)

CHF-1.80 (-0.74%)
Prev Close
CHF242.30
Open
CHF242.00
Day's High
CHF242.10
Day's Low
CHF238.40
Volume
2,406,576
Avg. Vol
1,516,864
52-wk High
CHF273.00
52-wk Low
CHF219.10

Summary

Name Age Since Current Position

Severin Schwan

50 2013 Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

57 2011 Non-Executive Chairman of the Board

Andre Hoffmann

58 Non-Executive Vice Chairman of the Board

Alan Hippe

50 2011 Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Stephan Feldhaus

55 2010 Member of the Enlarged Corporate Executive Committee, Head Group Communications

Sophie Kornowski-Bonnet

54 2012 Member of the Enlarged Corporate Executive Committee, Head Roche Partnering

Osamu Nagayama

70 2006 Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai

John Reed

59 2013 Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development

Michael Varney

59 2015 Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development

Cristina Wilbur

50 2016 Member of the Executive Committee, Head Group Human Resources

Urs Jaisli

61 Chief Compliance Officer

Gottlieb Keller

63 2008 Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors

Roland Diggelmann

50 2016 Member of the Corporate Executive Committee, Chief Executive Officer Roche Diagnostics

Daniel O'Day

53 2016 Member of the Corporate Executive Committee, Chief Executive Officer Roche Pharmaceuticals

Per-Olof Attinger

57 2010 Secretary to the Corporate Executive Committee

Pius Baschera

66 2007 Non-Executive Director

John Bell

64 2001 Non-Executive Director

Julie Brown

55 2016 Non-Executive Director

Paul Bulcke

63 2011 Non-Executive Director

Richard Lifton

64 2015 Non-Executive Director

Andreas Oeri

67 1996 Non-Executive Director

Bernard Poussot

65 2015 Non-Executive Director

Claudia Suessmuth Dyckerhoff

50 2016 Non-Executive Director

Peter Voser

59 2011 Non-Executive Director

Karl Mahler

Head of Investor Relations

Biographies

Name Description

Severin Schwan

Dr. Severin Schwan has been Chairman of the Corporate Executive Committee, Chief Executive Officer and Executive Director of Roche Holding Ltd since 2013. He was Chairman of the Corporate Executive Committee and Chief Executive Officer of Roche Holding AG from March 4, 2008. He was previously Chief Executive Officer of the Division Roche Diagnostics and Member of the Corporate Executive Committee at the Company from January 1, 2006. Between 1993 and 1995, he was a Trainee at Corporate Finance for Roche Basel. From 1995 until 1998, he was Head of Finance & Administration at Roche Brussels. From 1998 until 2000, Dr. Schwan was Head Finance & Informatics at Roche Grenzach, Germany and Member of the Executive Board of Roche Deutschland Holding GmbH. From 2000 until 2004, he was Head of Global Finance & Services at Roche Diagnostics, Basel. Since 2009, Dr. Schwan has been Member of the Board of Directors of Chugai Pharmaceuticals, Japan, and Member of the International Business Leaders Advisory Council for the Mayor of Shanghai (IBLAC). Dr. Schwan studied Economics at Universitaet Innsbruck, University of York and University of Oxford. He gained an Economics Degree from Innsbruck. He studied Law at Universitaet Innsbruck and gained a Law degree in 1991. Dr. Schwan then completed a Doctorate in Law at Universitaet Innsbruck in 1993 and Research studies at Universite Catholiques de Louvaine, Belgium.

Christoph Franz

Dr. Christoph Franz has been Non-Executive Chairman of the Board of Roche Holding Ltd since March 1, 2011. He is Member of the Remuneration Committee and Chairman of the Presidium/Nomination Committee at the Company. He began his career in 1991 with Deutsche Lufthansa AG. In 1994 he joined Deutsche Bahn AG and acted as Member of the Executive Board and CEO of passenger transport division. In 2004 he became Chief Executive Officer of Swiss International Air Lines AG. In 2009 Dr. Franz became Member of the Executive Board of Deutsche Lufthansa AG and Deputy to the Executive Board Chairman and CEO Lufthansa Passenger Airlines. Since January 2011 he has been Chairman of the Executive Board and Chief Executive Officer of Deutsche Lufthansa AG. He holds a Doctorate degree (Dr. rer. pol.) from Technische Universitaet Darmstadt (Darmstadt University of Technology).

Andre Hoffmann

Mr. Andre Hoffmann is Non-Executive Vice Chairman of the Board of Directors at Roche Holding Ltd. He also acts as Member of the Presidium/Nomination Committee, Corporate Governance and Sustainability Committee, as well as Chairman of the Remuneration Committee of the Company. He joined the Company’s Board of Directors in 1996. From 1977 until 1978, he studied at Universite de Geneve and from 1979 until 1982 he studied at St. Gallen School. In 1990, he received a Master of Business Administration degree from Institut Europeen d’Administration des Affaires (INSEAD). From 1985 until 1989, he worked for James Capel and Co., where his latest position was Manager, European Mergers & Acquisitions. From 1991 until 1993, he worked for Nestle UK Ltd., where his latest position was Special Project Manager, Food division. Since 1994, he worked in Private Investment Activities. Since 2000, he has been Member of the Board of Givaudan Ltd., Member of the Board of Glyndebourne Productions Ltd., and Chairman of Nemadi Advisors Ltd. Since 2003, he has been Member of the Board of Brunswick Capital Ltd. and Chairman of Living Planet Fund Management Co. He has served as Vice President of WWF International, Treasurer of Fondation les Corbillettes pour l'Aide aux enfants handicapes mentaux, Member of the Executive Committee of IRP, Institut International de Recherche en Paraplegie, Founding Member of Stiftung Patronatskomitee Kunstmuseum Basel, Board Member of Roche Research Foundation, International Council Member of Tate Gallery, Chairman of the Board of Fondation Pro Valat, Vice Chairman of the Board of Fondation Sansouire, Board Member of Takh, Association pour le Cheval de Przewalski, President of FIBA, Fondation Internationale du Banc d'Arguin, among others.

Alan Hippe

Dr. Alan Hippe has been Member of the Corporate Executive Committee, Chief Financial Officer and Information Technology Officer at Roche Holding Ltd since April 1, 2011. Between 1993 and 1996 Dr. Hippe was Research Assistant and Teaching Assistant at the Universities of Mainz and Mannheim. In 1996 he joined AVECO Holding AG as Head of group controlling and IT systems. He served as Member of the Executive Board of Continental AG from 2002 to 2009. Since April 2009 he has been Chief Financial Officer and Member of Executive Board of ThyssenKrupp AG.

Stephan Feldhaus

Dr. Stephan Feldhaus has been Member of the Enlarged Corporate Executive Committee and Head Group Communications at Roche Holding Ltd since August 1, 2010. He studied Roman Catholic Theology and Philosophy at Roman University of Muenster, Universitaet Zuerich and Lucerne and Ludwig-Maximilians-Universitaet Muenchen (University of Munich) and obtained his Doctorate in Theology (Dr. theol.) at the University of Munich in 1997. He started his career at Ludwig-Maximilians-Universitaet Muenchen (the University of Munich) as Scientific Assistant in 1989. He than worked for Cusanus Werk (Academic Foundation of the German bishops) as Scientific Assistant and Editor. In 1999, he joined Siemens AG.

Sophie Kornowski-Bonnet

Dr. Sophie Kornowski-Bonnet has been Member of the Enlarged Corporate Executive Committee and Head Roche Partnering at Roche Holding Ltd since February 1, 2012. She received an MBA in Marketing/Finance from the University of Chicago in 1989 and a Ph.D. in Pharmacy in 1986. Dr. Kornowski-Bonnet started her career in 1985 as Scientific Manager in Abbott Diagnostic Division. She held this position until 1987. In 1989 she moved on to become Marketing Research Analyst, Neuroscience Sales Representative for Abbott Pharmaceutical Products in Chicago. Between 1991 and 1994, she was Director, Strategic Marketing, Diagnostic Imaging at Sanofi Winthrop, after which she switched to the position of Director, Neuroscience Business Unit there. In 1996 Dr. Kornowski-Bonnet assumed the position of Director, Marketing Research and Strategic Planning at Merck Sharp & Dohme, and in 1997 was promoted to Managing Director there. From 2000 to 2002, she was Vice-President Arthritis and Analgesia Franchise at Merck & Co. Inc, where she held various positions within the following years. Dr. Kornowski-Bonnet joined the Roche group in 2007 as General Manager.

Osamu Nagayama

Mr. Osamu Nagayama has been Member of the Enlarged Corporate Executive Committee and Chairman and Chief Executive Officer Chugai at Roche Holding Ltd since 2006. Mr. Nagayama started his professional career in 1971 at the Long-Term Credit Bank of Japan. He joined Chugai Pharmaceutical Co. Ltd in 1978 and became its President in 1992. He studied at the Faculty of Business and Commerce at Keio University.

John Reed

Prof. Dr. John C. Reed, M.D., Ph.D., has been Member of the Enlarged Corporate Executive Committee and Head of Roche Pharma Research & Early Development at Roche Holding Ltd since April 2, 2013. He graduated from University of Virginia with B.A. degree in 1980. Moreover, he gained his M.D. and Ph.D. degrees at the University of Pennsylvania, School of Medicine, Philadelphia, the United States.

Michael Varney

Cristina Wilbur

Urs Jaisli

Gottlieb Keller

Dr. Gottlieb A. Keller has been Member of the Group Executive Committee, General Counsel and Secretary to the Board of Directors at Roche Holding Ltd since March 5, 2008. He was previously Head of Human Resources and Corporate Services, as well as Secretary to the Board of Directors and Member of Corporate Executive Committee at the Company as of 2004. In 1984, he joined the Corporate Law Department of the Roche Group. In 1989, he became Head of Business Development and Pharma Marketing Services of Roche Grenzach, Germany. In 1992, he became Assistant to the Chairman of the Board of Directors of Roche Holding Ltd. In 1996, he became Head of Human Resources at Hoffmann-La Roche Ltd, Germany. In 1998, he became Speaker of the Management Board of Hoffmann-La Roche Ltd, Germany. In 1999, he became Chairman of the Executive Board of Roche Deutschland Holding GmbH and then Secretary to the Board of Directors of Roche Holding Ltd and Corporate Compliance Officer of the Roche Group. In 2003, he became Member of the Corporate Executive Committee of the Roche Group and Head of Corporate Human Resources and Pharma Site Management in Basel and Kaiseraugst. In 2004, he became Head of Corporate Services and Human Resources. He is Committee Member of VSUD, President of the Board of Crocodil AG, Member of the Chairman's Committee of the Chamber of Commerce Germany-Switzerland, Member of the Board of Trustees of the Fritz Gerber Foundation for talented young people, Member of the Board of Trustees of the Paul Sacher Foundation and of swisscontact and Board Member of SGCI Chemie Pharma Schweiz and of economiesuisse. From 2003 until 2008, he was Board Member of the Basilea Pharmaceutica AG. Dr. Keller studied Law and Economics at Universitaet Basel and gained a Doctor of Law (Dr. iur) in 1980. He was admitted as Attorney in 1981 and became Notary Public of Basel in 1984 (not practicing).

Roland Diggelmann

Mr. Roland Diggelmann has been Member of the Corporate Executive Committee and Chief Executive Officer Roche Diagnostics at Roche Holding Ltd since 2016. He served as Member of the Corporate Executive Committee and Chief Operating Officer of the Division Roche Diagnostics of Roche Holding AG from September 1, 2012. He studied Administration at the University of Berne. Mr. Diggelmann started his career in 1995 by joining AlloPro AG as Manager Strategic Planning. In 1997 he switched to Sulzer Orthopedics Ltd, where he assumed the position of Director Strategic Planning & Marketing. In 1999 he became Executive VP Strategic Planning & Marketing there, and in 2001 - Executive VP Sales Asia Pacific. In 2002 Mr. Diggelmann was appointed Executive VP Sales Europe and Asia Pacific at Sulzer Medica/Centerpulse Ltd. In 2004, he became Senior VP Sales / Distribution EMEA and Managing Director at Zimmer GmbH. He joined the Company in 2008 as Head Region Asia Pacific.

Daniel O'Day

Mr. Daniel O'Day has been Member of the Corporate Executive Committee and Chief Executive Officer Roche Pharmaceuticals at Roche Holding Ltd since 2016. Prior to that, he was Member of the Corporate Executive Committee, Chief Operating Officer Division Roche Pharmaceuticals at Roche Holding AG from January 1, 2010. From 1987 to 1995 he held various commercial and sales roles at Roche Pharma in the United States, becoming Director of Human Resources in 1995. From 1996 he was Director of Product Marketing at Roche Pharma in the United States. From 1998 he worked for Roche Pharma HQ in Switzerland. From 2001 he acted at Roche Pharma in Japan as Head of Corporate Planning. In 2003 he became General Manager at Roche Pharma in Denmark. Since 2006, he has been President and Chief Executive Officer of Roche Molecular Diagnostics in the United States. He received a Bachelor of Science in Biology from the Georgetown University, Washington DC in 1986 and an MBA from Columbia University, New York in 1997.

Per-Olof Attinger

Mr. Per-Olof Attinger has been Secretary to the Corporate Executive Committee at Roche Holding Ltd since August 1, 2010. Mr. Attinger started his professional career in 1986 at Sandoz as Engineer responsible for Chemical Process Development. He has served at Roche since 1992, where he has occupied various managerial positons, including Manager of Mergers & Acquisitions, among others. In 1984, he obtained a degree in Chemical Engineering from the Federal Institute of Technology (ETH) Zurich. He than made Thesis at Imperial College in London and received his Masters degree in Busines Administration from European Institute for Business Administration (INSEAD) in 1992.

Pius Baschera

Prof. Dr. Pius Baschera has been Non-Executive Director at Roche Holding Ltd since March 5, 2007. He is Member of the Corporate Governance and Sustainability Committee of the Company. From 1979 to 1981, Prof. Dr. Baschera was Vice President Production Controlling at Hilti Corporation, Schaan, and from 1982 to 1984 he was Vice President Corporate Development Western Hemisphere at Hilti Inc. Tulsa, in the United States of America. In 1985, he became General Manager of Hilti (Switzerland) AG and from 1985 until 1989, General Manager of Hilti Deutschland GmbH. From 1989 until 1990, Prof. Dr. Baschera was Vice President Market Region Europe 1 at Hilti Corporation, Schaan, where he then worked as Member of Executive Board and Chief Financial Officer from 1990 until 1993 and Chief Executive Officer from 1994 until 2006. He then became Hilti Corporation’s Chairman of the Board of Directors in 2007. Prof. Dr. Baschera has served as Member of Advisory Board of Vorwerk and Ardex GmbH, as Chairman of the Board of Directors of Venture Incubator AG and as Member of Board of Directors of Schindler Holding AG. He studied Mechanical Engineering with Scientific Management at the Swiss Federal Institute of Technology in Zurich, where he gained a Doctorate and became Titular Professor.

John Bell

Prof. John Irving Bell has been Non-Executive Director of Roche Holding Ltd since 2001. In addition, he acts as Member of the Audit Committee of the Company. In 1975, he gained a Bachelor of Medical Science with Honors from the University of Alberta. In 1976, Prof. Sir Bell gained a Bachelor of Arts with Honors in Physiological Sciences from Magdalen College, Oxford University. In 1979, he gained a Bachelor of Medicine and Bachelor of Surgery (BM, BCh) from Magdalen College, Oxford University. In 1990, he gained a Doctor of Medicine (DM) from Magdalen College, Oxford University. From 1979 until 1982, he carried out postgraduate clinical training in Oxford and London. From 1982 until 1987, Prof. Sir Bell was Clinical Fellow in the Department of Medicine at Stanford University and also Postdoctoral Fellow in the Department of Medical Microbiology at Stanford University. From 1987 until 1989, he was Wellcome Senior Clinical Fellow and Honorary Consultant Physician in the Nuffield Departments of Clinical Medicine and Surgery at John Radcliffe Hospital, Oxford. From 1989 until 1992, he was University Lecturer at the Nuffield Department of Clinical Medicine at Oxford University. From 1992 until 2002, he was Nuffield Professor of Clinical Medicine at Oxford University. Since 2002, Prof. Sir Bell has been Regius Professor of Medicine at Oxford University. He is also has been Honorary Consultant Physician at Oxford Radcliffe NHS Trust since 1987; Nuffield Professor of Clinical Medicine Chairman at the Department of Medicine, Oxford University School of Medicine, since 1992; Founder of the Wellcome Trust Centre for Human Genetics since 1993; Chairman of the Partnership Board at the Oxford Centre for Diabetes, Endocrinology and Metabolism since 1999; Chairman of the Trials and Epidemiology Building, Oxford since 1999; and President of the Academy of Medical Sciences since 2006. He was knighted in the 2008 Honors list for Services to Medicine.

Julie Brown

Ms. Julie Brown has been Non-Executive Director of Roche Holding Ltd since March 1, 2016. She is Chairman of the Audit Committee at the Company.

Paul Bulcke

Mr. Paul Bulcke has been Non-Executive Director at Roche Holding Ltd since March 1, 2011. He is Member of the Audit Committee at the Company. He started his career in 1977 as Financial Analyst with Scott Graphics International. In 1979 he joined Nestle Group where he held several position including Marketing trainee, sales and division functions, Market Head at Nestle Portugal, Nestle Chech and Slovak Republic, as well as at Nestle Germany. Between 2004 and 2008, Mr. Bulcke acted as Executive Vice President, Nestle S.A. as well as Zone Director for Zone Americas: United States of America, Canada, Latin America and Caribbean. Mr. Bulcke has been Chief Executive Officer of Nestle S.A. since April 2008. He studied Commercial Engineering at Katholieke Universiteit Leuven, from which he graduated in 1976. Between 1976 and 1977 he attended postgraduate studies in Management at Vlerick Leuven Gent Management School (Universiteit Gent), and in 1995 he completed Program for Executive Development at Institute of Management Development (IMD) Switzerland.

Richard Lifton

Prof. Dr. Richard P. Lifton has been Non-Executive Director at Roche Holding Ltd since 2015. He is Member of the Remuneration Committee at the Company.

Andreas Oeri

Dr. Andreas Oeri, M.D., has been Non-Executive Director at Roche Holding Ltd since 1996. In addition, he acts as Chairman of the Corporate Governance and Sustainability Committee of the Company. From 1997 until 1985, he worked as Assistant Physician in the Surgical Clinic of the Cantonal Hospital (Kantonsspital) in Liestal, the Institute for Physical Medicine of the Cantonal Hospital (Kantonsspital) in Basel, the Surgical Department of the University of Basel and Basel University Orthopedic Hospital. From 1986 until 1988, Dr. Oeri was Acting Senior Physician of the Basel University Orthopedic Hospital. In 1988 he became a Specialist in Orthopedic Surgery (FMH). Since 1988, he has had his own practice for Orthopedic Surgery in Basel. Dr. Oeri completed Medical Studies at Universitaet Basel and holds a Swiss Medical Diploma as well as a Doctorate of Medicine.

Bernard Poussot

Mr. Bernard J. Poussot has been Non-Executive Director of Roche Holding Ltd since 2015. He is Member of the Remuneration Committee at the Company.

Claudia Suessmuth Dyckerhoff

Dr. Claudia Suessmuth Dyckerhoff has been Non-Executive Director of Roche Holding Ltd since March 1, 2016. She is Member of the Corporate Governance and Sustainability Committee and the Audit Committee at the Company.

Peter Voser

Mr. Peter R. Voser has been Non-Executive Director at Roche Holding Ltd since March 1, 2011. He is Member of the Remuneration Committee at the Company. He started his career in 1982 by joining the Royal Dutch Shell. He held there various finance and business roles in Switzerland, the United Kingdom, Argentina and Chile. In 1997 he became Group Chief Internal Auditor at the company and in 1999 he was appointed Chief Financial Officer (CFO) of Shell Europe Oil Products. In 2001 he became CFO of the Global Oil Products Business and Member of the Oil Products Executive Committee. Between 2002 and 2004, Mr. Voser acted as CFO and an Executive Committee Member of the Asea Brown Boveri (ABB) Group of Companies. From 2004 and 2009 he held the position of Chief Financial Officer (CFO) and an Executive Director of Royal Dutch Shell. Since 2009 he has been active as Chief Executive Officer of Royal Dutch Shell and since 2010, he has acted as Director of Catalyst. He studied Business Administration at Zuercher Hochschule fuer angewandte Wissenschaften, ZHAW (the University of Applied Sciences).

Karl Mahler